← all works
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.
No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Acute Ischemic Stroke Management
- Field
- Medicine
- Canadian institutions
- —
- Funders
- Medical Research CouncilChest Heart and Stroke ScotlandNational Health and Medical Research CouncilScottish Funding CouncilNorges ForskningsrådDalhousie UniversitySchweizerische HerzstiftungNational Research FoundationKarolinska InstitutetNational Institute for Health and Care ResearchUniversity of EdinburghStroke AssociationStockholms Läns LandstingNational Institute for Social Care and Health Research
- Keywords
- ThrombolysisIschaemic strokeMedicineRecombinant tissue plasminogen activatorStroke (engine)Randomized controlled trialTissue plasminogen activatorAcute strokeClinical trialEmergency medicineIntensive care medicineInternal medicineIschemic strokeIschemiaMyocardial infarction
- Has abstract in OpenAlex
- no